Orphan disease biotech Auspex Pharmaceuticals sets terms for $61 million IPO

By
A A A

Auspex Pharmaceuticals, a clinical-stage biotech developing treatments for orphan diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $61 million by offering 5.5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Auspex Pharmaceuticals would command a market value of $231 million.

Auspex Pharmaceuticals, which was founded in 2001, plans to list on the NASDAQ under the symbol ASPX. The company initially filed confidentially on November 21, 2013. Stifel and BMO Capital Markets are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: ASPX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

35,695,364
  • $16.51 ▼ 0.96%
30,250,827
  • $130.36 ▼ 1.08%
25,934,177
  • $34.2872 ▲ 0.82%
25,194,126
  • $34.69 ▲ 0.73%
25,044,083
  • $57.0453 ▲ 1.41%
23,680,747
  • $27.36 ▼ 0.98%
22,761,826
  • $18.44 ▲ 0.93%
18,637,282
  • $46.82 ▼ 1.33%
As of 5/29/2015, 02:47 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com